IRD (Opus Genetics) ROC (Joel Greenblatt) %: -134,823.90% (As of Mar. 2026)


IRD Opus Genetics Inc IRD
24 GF Score
Price $4.11
GF Value $0.37
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Opus Genetics ROC (Joel Greenblatt) %?

Opus Genetics IRD +1.48% 24 ROC (Joel Greenblatt) % is -134,823.90% as of Mar. 2026. GuruFocus rates IRD with a GF Score™ of 24/100 and a GF Value™ of $0.37 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,325 Biotechnology companies, Opus Genetics ranks worse than 96.83% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Opus Genetics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -134,823.90%.

The historical rank and industry rank for Opus Genetics's ROC (Joel Greenblatt) % or its related term are showing as below:

IRD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -472425   Med: -22830.16   Max: 227650
Current: -50047.55

During the past 7 years, Opus Genetics's highest ROC (Joel Greenblatt) % was 227650.00%. The lowest was -472425.00%. And the median was -22830.16%.

IRD's ROC (Joel Greenblatt) % is ranked worse than
96.83% of 1325 companies
in the Biotechnology industry
Industry Median: -297.52 vs IRD: -50047.55

Opus Genetics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Opus Genetics  (NAS:IRD) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Opus Genetics ROC (Joel Greenblatt) % Related Terms


Opus Genetics ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Opus Genetics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Opus Genetics ROC (Joel Greenblatt) % Chart

Opus Genetics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -472,425.00 227,650.00 -144,100.00 -22,830.16 -21,341.46

Opus Genetics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11,115.27 -15,322.15 -31,755.25 -29,440.39 -134,823.90

IRD vs PALI, VSTM, GALT: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, Opus Genetics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Opus Genetics ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Opus Genetics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Opus Genetics's ROC (Joel Greenblatt) % falls into.


IRD
24GF Score
Opus Genetics Inc IRD
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Opus Genetics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.995 + 0 + 1.788) - (7.781 + 0 + 0)
=-3.998

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.731 + 0 + 3.927) - (8.545 + 0 + 0.795)
=-3.682

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Opus Genetics for the quarter that ended in Mar. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-259.536/( ( (0.199 + max(-3.998, 0)) + (0.186 + max(-3.682, 0)) )/ 2 )
=-259.536/( ( 0.199 + 0.186 )/ 2 )
=-259.536/0.1925
=-134,823.90 %

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -134,823.90% mean?
Opus Genetics (IRD) has a ROC (Joel Greenblatt) % of -134,823.90% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Opus Genetics and its competitors. According to the industry distribution chart, Opus Genetics ranks #1283 out of 1325 companies in the Biotechnology industry, placing it in the top 96.8%.
Is Opus Genetics' ROC (Joel Greenblatt) % too high?
Opus Genetics' current ROC (Joel Greenblatt) % is -134,823.90%. Based on the distribution chart, Opus Genetics ranks #1283 out of 1325 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Opus Genetics has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Opus Genetics' ROC (Joel Greenblatt) % compare to PALI and VSTM?
According to the Biotechnology industry distribution chart, Opus Genetics ranks #1283 out of 1325 companies for ROC (Joel Greenblatt) %. This places Opus Genetics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Opus Genetics and its competitors. Opus Genetics's current ROC (Joel Greenblatt) % is -134,823.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Opus Genetics stock overvalued right now?
Based on GuruFocus' analysis, Opus Genetics (IRD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.37, compared to a current price of $4.11 — trading 1010.8% above its estimated fair value. The current ROC (Joel Greenblatt) % is -134,823.90%. Opus Genetics' overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Opus Genetics (IRD), the current ROC (Joel Greenblatt) % is -134,823.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Opus Genetics (IRD) Overvalued in 2026?

Based on GuruFocus' analysis, Opus Genetics stock appears to be overvalued. The current stock price of $4.11 is trading 1010.8% above its estimated GF Value™ of $0.37. GuruFocus considers Opus Genetics to be Significantly Overvalued.

Key valuation signals for IRD:

  • ROC (Joel Greenblatt) %: -134,823.90%
  • GF Value™: $0.37 vs. price of $4.11 (1010.8% above fair value)
  • GF Score™: 24/100 with 4 warning signs

No single metric tells the full story. See the IRD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Opus Genetics Business Description

Other Exchanges R3X1:Germany
Address 8 Davis Drive, Suite 220, Durham, NC, USA, 27713
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
24GF Score

Get the complete analysis for IRD

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.11
Price
$0.37
GF Value